Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBATE: Neoadjuvant Durvalumab + Gem/Cis in Localized BTC
NCT04308174Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- May 2020
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in biliary tract cancer (BTC), sponsored by Asan Medical Center. Started May 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04308174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308174.